15 Comments
 
Most Helpful

Modeling in biotech is all probability of success weighted SOTP and DCF, so be comfortable talking about that. Revenue builds are market models with a patient build and average selling price.

Drug will get developed/approved and eventually lose exclusivity after a certain # of years, so need to constantly derisking revenue forecast by adding on to the pipeline through R&D, acquisitions, or commercialization partnerships.

Some trends: large pharma has lots of cash right now to be acquisitive and buy down SMID names whos valuation is getting pushed down lately.

All of this should be a good starting point, can’t imagine you get asked anything too in-depth.

 

Some things for you to think about:

What are key aspects to focus on to assess a drug?

MOA, modality, development stage, indication

Find the DB “pharmaceuticals for beginner” if uou have access to research - it’s from 2012 but will give you good overview of drug development process

There is a cohen report on the fda approval process too - recently updated

How to think about development timelines, PTRS, peak sales, typical cost ratios

When do companies get bought? What do buyers wait to see before pressing the button?

Who are the buyers?

How do they assess a project? (Risk adjusted vs non adjusted, IRR + NPV, payback, value share…)

If you google “biotech caluation model xls” you’ll find a sample model from BIWS on Jazz. Worth taking a look at

 
pipole4

Some things for you to think about:

What are key aspects to focus on to assess a drug?

MOA, modality, development stage, indication

Find the DB “pharmaceuticals for beginner” if uou have access to research - it’s from 2012 but will give you good overview of drug development process

There is a cohen report on the fda approval process too - recently updated

How to think about development timelines, PTRS, peak sales, typical cost ratios

When do companies get bought? What do buyers wait to see before pressing the button?

Who are the buyers?

How do they assess a project? (Risk adjusted vs non adjusted, IRR + NPV, payback, value share…)

If you google “biotech caluation model xls” you’ll find a sample model from BIWS on Jazz. Worth taking a look at

I wasn't able to find the BIWS model, any chance you could link me to it?

 

Types of M&A in biopharma are going to different. You will see a lot of deals with upfront + CVRs upon clinical/regulatory/commercial milestones. Also a lot of asset level licensing deals, where the client isn’t selling the entire company but only the commercial rights to a drug in a licensed territory (can be US/WW/ex-US…..etc) in exchange for an upfront + milestones + tiered royalty streams based on future sales of the product

 

Sed iste doloribus quasi quo quia officiis praesentium. Ea quaerat ut est aliquid quas tempora. Ut repellat eum eveniet quia. Odit quia minus sit aut vitae. Quo iusto veniam accusamus eum qui iste. Accusamus officia veniam eos nostrum id earum.

Assumenda consequuntur dolores reiciendis suscipit. Harum vel ut et provident. Explicabo rem praesentium natus incidunt rem repellat quam. Nam dolores sequi qui ut. Laboriosam repellat praesentium culpa aliquam distinctio. Eius sit fugit nam atque.

Doloremque deserunt dolor et ut et iste. Nesciunt illo voluptatem iste omnis. Quisquam id eligendi porro. Reiciendis amet quia nemo voluptatibus sit omnis suscipit voluptas.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.2%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.2%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.8%
  • JPMorgan 01 97.2%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (48) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (83) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
GameTheory's picture
GameTheory
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
CompBanker's picture
CompBanker
98.9
9
dosk17's picture
dosk17
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”